Archive for February, 2010

Blood Test Might Sort Out Milk Allergies

Sunday, February 28th, 2010

SATURDAY, Feb. 27 — A blood test may help identify children with milk allergy who can tolerate baked-milk products and those who may have a serious allergic reaction to any form of cow’s milk, a new study shows.
Previous research found that up to…



Lees meer..

Avoiding Dairy Due To Lactose Intolerance Is Unnecessary In Most Cases

Sunday, February 28th, 2010

People may avoid milk and other dairy products due to concerns about lactose intolerance, but eliminating these nutrient-rich foods may not only be unnecessary to manage the condition – it could impact diet and health, concludes a panel of experts assembled by the National Institutes of Health (NIH)…
Lees meer..

In Children With Autism Spectrum Disorder, A Mother’s Sensitivity May Help Language Growth

Sunday, February 28th, 2010

A new study by researchers from the University of Miami shows that maternal sensitivity may influence language development among children who go on to develop autism. Although parenting styles are not considered as a cause for autism, this report examines how early parenting can promote resiliency in this population…
Lees meer..

Vion Pharmaceuticals Receives Response From FDA On Special Protocol Assessment For Onrigin(TM)

Sunday, February 28th, 2010

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VIONQ) announced that it had received a response from the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (“SPA”) for its oncology therapeutic Onrigin™ (laromustine) Injection…
Lees meer..

Supelco(R) Introduces Breakthrough In Bioseparations Performance — Ascentis(R) Express ES-C18 HPLC Columns

Sunday, February 28th, 2010

Supelco, a division of Sigma-Aldrich® (Nasdaq: SIAL), announced the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core™ particle design…
Lees meer..

CDC’s Advisory Committee On Immunization Practices Recommends Pfizer’s Prevnar 13™ Vaccine For The Prevention Of Invasive Pneumococcal Disease

Sunday, February 28th, 2010

Pfizer Inc (NYSE:PFE) announced that the United States Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for healthy children aged 2 months through 59 months for the prevention of invasive pneumococcal disease…
Lees meer..

Forest Laboratories Receives Decision From FDA For Supplemental New Drug Application For Bystolic(R)

Sunday, February 28th, 2010

Forest Laboratories, Inc. (NYSE: FRX) announced that the U.S. Food and Drug Administration (FDA) did not approve the additional indication for Bystolic(R) (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA). Bystolic is currently approved in the US for the treatment of hypertension…
Lees meer..

U.S. Food And Drug Administration Approves Cayston(R) For The Improvement Of Respiratory Symptoms In Cystic Fibrosis Patients

Sunday, February 28th, 2010

Gilead Sciences, Inc. (Nasdaq:GILD) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston(R)(aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (P. aeruginosa)…
Lees meer..

Avastin Phase III Study Shows Positive Results In Women With Advanced Ovarian Cancer

Sunday, February 28th, 2010

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone…
Lees meer..

Shire Announces FDA Approval Of VPRIV(TM) (velaglucerase Alfa For Injection) For The Treatment Of Type 1 Gaucher Disease

Sunday, February 28th, 2010

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VPRIV, a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of Type 1 Gaucher disease in pediatric and adult patients…
Lees meer..